AstraZeneca buying MedImmune

British pharmaceutical giant AstraZeneca announced it is acquiring Gaithersburg, Md.-based MedImmune for $15.6 billion. The deal, which is expected to close in June, will allow AstraZeneca to gain a presence in the increasingly lucrative vaccines market. It will also reportedly increase the company's proportion of biotechnology drugs in its pipeline to 27%, from 7%, and enlarge its total pipeline by 45 projects, to 163 projects.

To see more Hot off the Press news articles, click here.

To go to the Drug Topics homepage, click here.